Pledging

These are the original issues in this subcategory

ROBOCALLS
TELEMARKETING FRAUD
PHARMACEUTICAL ADS

Winning Issue » PHARMACEUTICAL ADS

For decades, the pharmaceutical industry has claimed that research costs are the reason American drugs are so expensive compared to the rest of the world. However, facts show that many of these firms spend more on advertising than on research, some more than twice as much. For several years now, Americans have been bombarded with TV ads for prescription medications. In 2024, pharmaceutical manufacturers spent more than $10 billion on direct-to-consumer television, radio, online, magazine and newspaper advertising. Drug makers now market their products directly to consumers, rather than the traditional method of allowing doctors to make treatment recommendations. Pharmaceutical companies often air ads for products that treat sexual dysfunction, incontinence, pain, hormone imbalance or depression -followed by lengthy warnings of possible horrific side-effects from using their products. Some critics claim these types of ads are not appropriate to be viewed by children. They also say drug ads are not produced by people who are experts in healthcare, but who are somewhat competent in sales and marketing. Advocates say these ads should be considered for what they are, a promotion, not a source of factual consumer information. They claim most consumers are not adequately informed to assess the accuracy or truth of a drug ad, or whether it is appropriate for their condition, or if they even have a condition that requires such medication.

Pending Legislation: H.R.1117 - Responsibility in Drug Advertising Act of 2025
Sponsor: Rep. Rosa DeLauro (CT)
Status: House Committee on Energy and Commerce
Chair: Rep. Brett Guthrie (KY)

Polling Options

I oppose reforming current pharmaceutical advertising policy and wish to donate resources to the campaign committee of Speaker Mike Johnson (LA).

I support prohibiting direct-to-consumer (DTC) advertising of new prescription drugs for the first three years after their approval by the Food and Drug Administration (FDA)by: 1.) Banning advertising of new drugs to consumers for three years following FDA approval. This includes advertising on social media and other platforms. 2.) Allowing the FDA to grant a waiver allowing a drug's sponsor to advertise if the FDA determines it would have an "affirmative value to public health” in the third year of probation. 3.) Extending the advertising ban beyond the three-year period if post-approval studies or adverse event reports indicate the drug has "significant adverse health effects". And wish to donate resources to the campaign committee of Rep. Brett Guthrie (KY) and/or to an advocate group currently working with this issue.

Winning Option

I support prohibiting direct-to-consumer (DTC) advertising of new prescription drugs for the first three years after their approval by the Food and Drug Administration (FDA)by:

1.) Banning advertising of new drugs to consumers for three years following FDA approval. This includes advertising on social media and other platforms.

2.) Allowing the FDA to grant a waiver allowing a drug's sponsor to advertise if the FDA determines it would have an "affirmative value to public health” in the third year of probation.

3.) Extending the advertising ban beyond the three-year period if post-approval studies or adverse event reports indicate the drug has "significant adverse health effects".

And wish to donate resources to the campaign committee of Rep. Brett Guthrie (KY) and/or to an advocate group currently working with this issue.

You May Pledge Your Support For This Issue With A Monetary
Donation And By Writing A Letter To Your Representatives

Please login to pledge

Pledge Period - Opening Date

February 2, 2026 @00:01 Universal Coordinated Time (UTC)

Pledge Period - Closing Date

February 8, 2026 @23:59 Universal Coordinated Time (UTC)

Trustee Election - Begins

February 9, 2026